Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.33 |
| ▸ | EDNRA | P25101 | 9/20 | 0.33 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014513 | 0.91 | EDNRA (0.36) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7018948 | 0.89 | EDNRA (0.35) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7026270 | 0.86 | EDNRA (0.34) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7014711 | 0.85 | EDNRA (0.38) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7018171 | 0.84 | EDNRB (0.40) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7163555 | 0.83 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL7021452 | 0.81 | EDNRA (0.42) | EDNRBEDNRA | |
| SCHEMBL7021400 | 0.81 | EDNRA (0.33) | EDNRBEDNRA | |
| SCHEMBL7019244 | 0.80 | EDNRA (0.37) | EDNRBEDNRAABCC3ABCC4ABCB11 | |
| SCHEMBL7023502 | 0.79 | EDNRA (0.42) | EDNRBEDNRAABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0898571-B1 | THIENO-PYRIDINE SULFONAMIDES, DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-6545014-B2 | Glaucoma; adjusting concentration of nitric oxide; hypotensive, antispasmodic, antiischemic, cardiotonic agents; bronchodilators; urogentital disorders; agonists, antagonists for endothelin receptors | TEXAS BIOTECHNOLOGY CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020028829-A1 | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-03-07 | — | — | US | disclosed |
| US-6329387-B2 | ANTIHISTAMINE, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | TEXAS BIOTECHNOLOGY CORPORATION. | 2001-12-11 | — | — | US | disclosed |
| US-20010014684-A1 | THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-08-16 | — | — | US | disclosed |
| US-6013655-A | HYPOTENSIVE AGENTS; RESPIRATORY SYSTEM DIISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028829-A1 | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin | EDNRB, EDNRA, AGTR2 | EDNRB 1/4885EDNRA 2/4885ABCC3 815/4885 |
| US-20010014684-A1 | THIENO-PYRIDINE SULFONAMIDES DERIVATIVES THEREOF AND RELATED COMPOUNDS THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRB, EDNRA, AGTR1 | EDNRB 1/4885EDNRA 2/4885ABCC3 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.